VRG Tx is an AI-powered miniprotein platform CGT and peptide company with combined in silico and wetlab capabilities. Combining AI-powered interaction modeling with NGS-based advanced analytics, VRG Tx designs novel therapeutic candidates with unprecedented selectivity and affinity in an extremely fast discovery process. Miniproteins combine the benefits of small molecules and biologics. VRG Tx’s forerunning project, available for in-licensing or investment, is a selective Kv1.3 inhibitor for autoimmune diseases (Atopic dermatitis, Psoriasis, IBD) with proven in vivo efficacy. VRG Tx is committed to leveraging its miniprotein platform (integrating ISEP and WISDOM technology) to tackle diseases that conventional biopharma cannot reach. The Wetlab-verified In Silico Design of Miniproteins (WISDOM) and Individual Sequence Enrichment Pattern (ISEP) technologies build on the evolutionary conserved structures of natural peptides and applies both in silico and in vitro HTS screenings.